Generic Name: Micardis hct
What is Micardis Hct?
To minimize dose-independent side effects, it is usually appropriate to begin combination therapy only after a patient has failed to achieve the desired effect with monotherapy. Therapy with any combination of telmisartan and hydrochlorothiazide will be associated with both sets of dose-independent side effects. MICARDIS HCT tablets are available as tablets containing either telmisartan 40 mg and hydrochlorothiazide 12.
In patients with more severe renal impairment, loop diuretics are preferred to thiazides, so MICARDIS HCT tablets are not recommended. MICARDIS HCT tablets are not recommended for patients with severe hepatic impairment. To view updated drug label links, paste the RSS feed address URL shown below into a RSS reader, or use a browser which supports RSS feeds, such as Safari for Mac OS X.
If you no longer wish to have this DailyMed RSS service, simply delete the copied URL from your RSS Reader. Due to inconsistencies between the drug labels on DailyMed and the pill images provided by RxImage, we no longer display the RxImage pill images associated with drug labels.
Take MICARDIS HCT once each day. Take MICARDIS HCT tablets with or without food. If you take too much MICARDIS HCT, call your doctor, or go to the nearest hospital emergency room right away. Talk with your doctor if you do not understand the instructions. What are the possible side effects of MICARDIS HCT tablets.
MICARDIS HCT tablets may cause serious side effects, including: Injury or death to your unborn baby. Kidney problems, which may get worse if you already have kidney disease. You may have changes in your kidney test results, and you may need a lower dose of MICARDIS HCT tablets.
Call your doctor if you get: swelling in your feet, ankles, or hands unexplained weight gain Call your doctor right away if you get any of the symptoms listed above.
Liver problems, which may get worse in people who already have liver problems and take MICARDIS HCT.
How should I take Micardis Hct?
Telmisartan does not bind to or block other hormone receptors or ion channels known to be important in cardiovascular regulation.
The renin-aldosterone link is mediated by angiotensin II, so coadministration of an angiotensin II receptor antagonist tends to reverse the potassium loss associated with these diuretics. The pharmacokinetics of orally administered telmisartan are nonlinear over the dose range 20-160 mg, with greater than proportional increases of plasma concentrations Cmax and AUC with increasing doses.
Gender: Plasma concentrations of telmisartan are generally 2-3 times higher in females than in males. Renal Insufficiency: Renal excretion does not contribute to the clearance of telmisartan. Plasma concentration of angiotensin II and plasma renin activity PRA increased in a dose-dependent manner after single administration of telmisartan to healthy subjects and repeated administration to hypertensive patients.
What should I avoid while taking Micardis Hct?
If hypotension occurs, the patient should be placed in a supine position, with salt and volume replacements given quickly. MicardisPlus is a combination of an angiotensin II receptor antagonist, telmisartan, and a thiazide diuretic, hydrochlorothiazide. The combination of these ingredients has an additive antihypertensive effect, reducing blood pressure to a greater degree than either component alone.
MicardisPlus once daily produces effective and smooth reductions in blood pressure across the therapeutic dose range. Telmisartan is an orally effective and specific angiotensin II receptor subtype 1 AT1 antagonist. Telmisartan displaces angiotensin II with very high affinity from its binding site at the AT1 receptor subtype, which is responsible for the known actions of angiotensin II.
Micardis Hct side effects
There is a risk of fetal or neonatal jaundice, thrombocytopenia, and possibly other adverse reactions that have occurred in adults. These adverse outcomes are usually associated with use of these drugs in the second and third trimester of pregnancy. Most epidemiologic studies examining fetal abnormalities after exposure to antihypertensive use in the first trimester have not distinguished drugs affecting the renin-angiotensin system from other antihypertensive agents.
In the unusual case that there is no appropriate alternative to therapy with drugs affecting the reninangiotensin system for a particular patient, apprise the mother of the potential risk to the fetus.
Perform serial ultrasound examinations to assess the intra-amniotic environment.
Common Micardis Hct ide effects may include:
There are thirty-one drug master file entries for this compound.
Micardis HCT may also cause severe side effects in some people.
Information is for End User's use only and may not be sold, redistributed or otherwise used for commercial purposes.
This has been true for most, but not all, angiotensin II antagonists and ACE inhibitors.
Where can I get more information?
Pediatric Use Safety and effectiveness of MICARDIS HCT in pediatric patients have not been established.
Heat pretreatment did not significantly alter cAMP and cGMP levels despite significantly increased ser16-HSP20 phosphorylation and suppressed force.